Kiniksa Pharmaceuticals, Ltd.
ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
Last updated:
Abstract:
The invention provides anti-oncostatin M receptor-.beta. (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
Status:
Application
Type:
Utility
Filling date:
3 Sep 2021
Issue date:
24 Feb 2022